Recombinant Human N-myc proto-oncogene protein (MYCN)

In Stock
Code CSB-YP015278HU
Size $250
Order now
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
  • The purity of MYCN was greater than 90% as determined by SEC-HPLC
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Greater than 90% as determined by SDS-PAGE.
Greater than 90% as determined by SEC-HPLC.
Target Names
Uniprot No.
Research Area
Alternative Names
bHLHe37; Class E basic helix-loop-helix protein 37; MODED; mycn; MYCN_HUMAN; N myc; N myc proto oncogene protein; N-myc proto-oncogene protein; Neuroblastoma derived v myc avian myelocytomatosis viral related oncogene; Neuroblastoma MYC oncogene; NMYC; NMYC proto oncogene protein; ODED; Oncogene NMYC; pp65/67; V myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog; v myc avian myelocytomatosis viral related oncogene neuroblastoma derived; v myc myelocytomatosis viral related oncogene neuroblastoma derived
Homo sapiens (Human)
Expression Region
Target Protein Sequence
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight
Protein Length
Full Length
Tag Info
N-terminal 6xHis-tagged
Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Tris-based buffer,50% glycerol
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
3-7 business days
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.

This Recombinant Human MYCN protein is an essential resource for cancer researchers. N-myc proto-oncogene protein, also known as Class E basic helix-loop-helix protein 37 (bHLHe37), plays a critical role in cancer research. This full-length protein (1-464aa) is expressed in yeast and serves as a powerful tool in various oncology applications.

Equipped with an N-terminal 6xHis-tag, our Recombinant Human MYCN protein facilitates effortless purification and detection. With a purity greater than 90% as determined by SDS-PAGE, you can rely on the exceptional quality of this protein to advance your cancer research projects. Choose between liquid and lyophilized powder forms to best suit your experimental requirements and elevate your research with our Recombinant Human MYCN protein.

Customer Reviews and Q&A

 Customer Reviews
Average Rating:
5.0 - 1 reviews

Submit a Review here

Applications : Pull-down assays of recombinant proteins

Review: In vitro glutathione S-transferase (GST) pull-down assay with recombinant GST-CCNT1, GST-CDK9, and GST-EAF1 together with His-tagged MYCN proteins demonstrated that MYCN directly binds to EAF1 with the highest affinity.

By Anonymous

Target Background

Positively regulates the transcription of MYCNOS in neuroblastoma cells.
Gene References into Functions
  1. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets. PMID: 30451831
  2. This suggested that NMyc regulated survival and growth of CHP134 and BE2C neuroblastoma cells, potentially through Wnt/betacatenin signaling. Furthermore, associated proteins, NMyc and STAT interactor and dickkopf Wnt signaling pathway inhibitor 1, were demonstrated to be involved in this regulation. PMID: 29749516
  3. In this report, we present a case with Feingold Syndrome having a novel mutation in MYCN gene and discuss genetic counselling and prenatal diagnosis due to pregnancy of the patient's mother. PMID: 30204967
  4. Results demonstrated that MYCN expression was downregulated in cholangiocarcinoma (CCA) through a mechanism involving miR-5095 binding its 3'UTR. PMID: 29620172
  5. MYCN levels are regulated transcriptionally by MYCNOS-01 (an alternative transcript of MYCNOS) in rhabdomyosarcoma and neuroblastoma cells. PMID: 29466962
  6. a MycN/CIP2A-mediated cell-fate bias may reflect a possible mechanism underlying early priming of some aggressive forms of neuroblastoma. PMID: 30021854
  7. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma. PMID: 29322842
  8. Data indicate that inter-play between MYCN and the highly tumorigenic proteins which are upregulated in the malignant IMR-32 neuroblastoma cells may be fueling their aggressive behavior. PMID: 29328367
  9. these results suggest that MYCN serves as a prognostic biomarker and therapeutic target of ACR for liver cancer stem cell in de novo Hepatocellular carcinoma. PMID: 29686061
  10. Alternative nonhomologous DNA end-joining pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation have been revealed in the process of neuroblastoma initiation in mice. PMID: 29238067
  11. High TrkA expression is one of the most powerful predictor of good prognosis in neuroblastoma and is associated with younger age, lower stage, and absence of MYCN amplification PMID: 29018959
  12. overexpression of MYCN promoted cell proliferation, and induced erythroid differentiation block and apoptosis resistance to cytotoxic agent. Knockdown of MYCN inhibited the expression of EZH2, and then activated p21 expression through removal of H3K27me3 at the p21 promoter. PMID: 29022893
  13. MAX to MYCN ratio that can account for tumour progression and clinical outcome in neuroblastoma. PMID: 29408445
  14. MYCN expression is regulated by ZAR1 in neuroblastoma. PMID: 28791558
  15. The target of miR-29b was predicted using miRanda, TargetScan and PicTar sofeware and authors also found MYCN was a direct target of miR-29b in glioma cells and miR-29b inhibited the proliferation of glioma cells via MYCN dependent way. PMID: 28423357
  16. eEF2K protects MYCN overexpressing NB cells from ND in vitro and in vivo, highlighting this kinase as a critical mediator of the adaptive response of MYCN amplified NB cells to metabolic stress. PMID: 28574509
  17. Among 30 samples of brain tumor, 14 cases revealed MYCN amplification. High-protein expression of MYCN was also observed in 43.3% of patients. There was a significant correlation between MYCN gene amplification and protein expression, interestingly five case showed discrepancy between the gene amplification and protein expression. PMID: 28453467
  18. PRMT1 has a role in regulating MYCN in neuroblastoma PMID: 27571165
  19. N-myc levels appear to be modulated by the antagonistic interactions of both miR-17, as a negative regulator, and HuD, as a positive regulator in N-myc-amplified neuroblastoma cells. PMID: 28560387
  20. We also propose a model for the stabilization mechanism in which binding to Aurora-A alters how N-Myc interacts with SCF(FbxW7) to disfavor the generation of Lys48-linked polyubiquitin chains PMID: 27837025
  21. This study provides a novel insight for miR-221 in the control of neuroblastoma cell proliferation and tumorigenesis, suggesting potentials of miR-221 as a prognosis marker and therapeutic target for patients with MYCN overexpressing neuroblastoma. PMID: 28003306
  22. N-MYC is in the downstream-regulated gene family in reprogramming cancer metabolism under hypoxia [review] PMID: 27447861
  23. SNHG1 is up-regulated by MYCN amplification and could be a potential prognostic biomarker for high-risk neuroblastoma intervention. PMID: 27517149
  24. MYCN expression is a marker indicative of likely clinical sensitivity to mTOR inhibition in neuroblastoma cells PMID: 27438153
  25. Results show that MYCN and LSD1 co-localize at NDRG1 promoter and repress its expression in neuroblastoma cells. PMID: 27894074
  26. Data indicate cross-talks between MYCN and beta-catenin signalling, which repress normal beta-catenin mediated transcriptional regulation. PMID: 27531891
  27. Data show that transcription factor activating enhancer binding protein-4 (TFAP4) is a direct transcriptional target of MYCN in neuroblastoma and that high levels of this transcription factor are associated with poor clinical outcome in this disease. PMID: 27448979
  28. data extend knowledge on roles of MCPIP1 in our model and link the protein to regulation of expression and stability of MYCN through decrease of signaling via Akt/mTOR pathway. PMID: 27935099
  29. Data show that MYCN and its regulated microRNAs acted together to repress the tumor suppressor genes. PMID: 27167114
  30. Common genetic variation predisposes to different neuroblastoma genotypes, including the likelihood of somatic MYCN-amplification. [meta-analysis] PMID: 29117357
  31. Results establish evidence that high MYCN amplification can be present in retinoblastoma with or without coding sequence mutations in the RB1 gene. PMID: 28211617
  32. The study conducted metabolic profiling of pre-malignant sympathetic ganglia and tumors derived from the TH-MYCN mouse model of neuroblastoma, that overexpresses human MYCN and compared to non-malignant ganglia from wildtype littermates. These results identify enhanced glutathione biosynthesis as a selective metabolic adaptation required for initiation of MYCN-driven neuroblastoma. PMID: 26996379
  33. Many prognostic signatures for neuroblastoma are confounded by MYCN amplification. PMID: 27599694
  34. Increasing MYCN copy number is associated with an increasingly higher rate of unfavorable clinical/biological features, with 11q aberration being an exception. Patients with MYCN gain appear to have inferior outcomes, especially in otherwise more favorable groups. PMID: 28696504
  35. miR-21 enhances chemo-resistance in tongue cancer cells via directly targeting CADM1, and an inverse correlation between miR-21 and CADM1 expression in vivo. MiR-21 overexpression is attributed to MYCN-mediated transcriptional regulation, which is also predictive for a worse prognosis in tongue cancer PMID: 27055844
  36. LMO1 is an important oncogene that promotes neuroblastoma initiation, progression, and widespread metastatic dissemination. PMID: 28867147
  37. our results identify DOT1L as a novel cofactor in N-Myc-mediated transcriptional activation of target genes and neuroblastoma oncogenesis. Furthermore, they characterize DOT1L inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma. PMID: 28209620
  38. CCCTC-binding factor (CTCF) targets the binding sites within MYCN promoter to facilitate its expression in neuroblastoma (NB) cells. PMID: 26549029
  39. PAX3-FOXO1 collaborates with MYCN during early rhabdomyosarcoma (RMS) tumourigenesis to dysregulate proliferation and inhibit myogenic differentiation and cell death. PMID: 28138962
  40. The findings reveal a PLK1-Fbw7-Myc signaling circuit that underlies tumorigenesis and validate PLK1 inhibitors, alone or with Bcl2 antagonists, as potential effective therapeutics for MYC-overexpressing cancers. PMID: 27773673
  41. Results show that N-Myc overexpression leads to the development of poorly differentiated, invasive prostate cancer that is molecularly similar to human NEPC. PMID: 27728805
  42. Rac activity may be an important determinant of metastatic capability in subsets of neuroblastoma cells lacking MYCN amplification. PMID: 27224546
  43. MYCN Gene Amplification is associated with Neuroblastoma. PMID: 27513929
  44. MYCN overexpression combined with activated anaplastic lymphoma kinase (ALK) is sufficient to induce neuroblastoma (NB) in mouse sympathoadrenal cells PMID: 27707976
  45. MYCN amplification can be heterogeneous between tumor sites, during tumor progression or following treatment, challenging the notion that MYCN copy number does not change for a particular neuroblastoma. PMID: 27465929
  46. High MycN expression is associated with low radiosensitivity in neuroblastoma. PMID: 27432152
  47. applying loss-and-gain function analysis, we demonstrated that miR-34a directly targeted to MYCN to sensitize NSCLC cells to cisplatin. In addition, p53 was found to monitor the expression of miR-34a in NSCLC cells after cisplatin treatment. Therefore, the sensitivity of cisplatin in NSCLC cells was modulated via p53/miR-34a/MYCN axis. PMID: 27836543
  48. Data supports our hypothesis that a positive-feedback loop of sonic hedgehog signaling induced INSM1 through N-myc and INSM1 enhanced N-myc stability contributing to the transformation of human neuroblastoma. PMID: 26456864
  49. Data show that v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) was overexpressed in non-small cell lung cancer (NSCLC) tumor tissues and cell lines, suggesting that targeting MYCN might provide beneficial effects for the clinical therapy of NSCLC. PMID: 27449038
  50. That initial decision to deny coverage could have had untoward health implications for this child, as the identification of constitutional MYCN duplication necessitated surveillance imaging for a number of pediatric malignancies associated with MYCN PMID: 27794475

Show More

Hide All

Involvement in disease
Feingold syndrome 1 (FGLDS1)
Subcellular Location
Tissue Specificity
Expressed in the neuronal cells of the cerebrum, neuroblastomas and thyroid tumors (at protein level).
Database Links

HGNC: 7559

OMIM: 164280

KEGG: hsa:4613

STRING: 9606.ENSP00000281043

UniGene: Hs.25960

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details


II. Contact details


III. Ship To


IV. Bill To